4.7 Article

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+lymphomas

Journal

JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 11, Issue 8, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2023-006959

Keywords

Immunotherapy; Receptors; Chimeric Antigen; Hematologic Neoplasms

Ask authors/readers for more resources

Chimeric antigen receptor (CAR)-T cells targeting CD30 have shown high response rates and durable remissions in relapsed/refractory CD30+ hematologic malignancies, particularly classical Hodgkin lymphoma. This therapy has low toxicity rates and no neurotoxicity in our phase 2 study. Patient-reported outcomes (PROs) collected in our clinical trial showed that physical function and symptom burden of patients treated with CD30-directed CAR-T cells recovered to at least their baseline health by 1 month post infusion.
Chimeric antigen receptor (CAR)-T cells targeting CD30 have demonstrated high response rates with durable remissions observed in a subset of patients with relapsed/refractory CD30+ hematologic malignancies, particularly classical Hodgkin lymphoma. This therapy has low rates of toxicity including cytokine release syndrome with no neurotoxicity observed in our phase 2 study. We collected patient-reported outcomes (PROs) on patients treated with CD30 directed CAR-T cells to evaluate the impact of this therapy on their symptom experience. We collected PROs including PROMIS (Patient-Reported Outcomes Measurement Information System) Global Health and Physical Function questionnaires and selected symptom questions from the NCI PRO-CTCAE in patients enrolled on our clinical trial of CD30-directed CAR-T cells at procurement, at time of CAR-T cell infusion, and at various time points post treatment. We compared PROMIS scores and overall symptom burden between pre-procurement, time of infusion, and at 4 weeks post infusion. At least one PRO measurement during the study period was found in 23 out of the 28 enrolled patients. Patient overall symptom burden, global health and mental health, and physical function were at or above baseline levels at 4 weeks post CAR-T cell infusion. In addition, PROMIS scores for patients who participated in the clinical trial were similar to the average healthy population. CD30 CAR-T cell therapy has a favorable toxicity profile with patient physical function and symptom burden recovering to at least their baseline pretreatment health by 1 month post infusion. Trial registration number: .

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available